Imidazoline receptor agonists: more than blood pressure reduction?
Abstract
The review contains original data and international studies’ results demonstrating that selective I1 imidazoline receptor agonists, and, in particular, Albarel®, a new sympatholytic agent, provide not only adequate and longterm blood pressure control, but also other beneficial metabolic and vascular effects. Most important ones are insulin resistance reduction, improvement of endothelial function and elasticity in middle-sized and large vessels. In Russian guidelines on arterial hypertension diagnostics and treatment, this medication class is recommended in patients with metabolic disturbances. Nevertheless, in real-world clinical practice, the indications might be widened, including sympathetic hyperactivity in post-menopause women, patients with insulin resistance, chronic obstructive pulmonary disease, and bronchial asthma.
About the Authors
D. V. Nebieridze
State Research Center for Preventive Medicine, Russian Federal Agency of Health and Social Development. Moscow
Russian Federation
Russian Federation
S. V. Nedogoda
Volgograd State Medical Academy. Volgograd
Russian Federation
Russian Federation
References
1. Рекомендации по профилактике, диагностике и лечению артериальной гипертензии. Артер гиперт 2001; 7(1): 4-16.
2. Bousquet P, Feldman J, Schwartz J. Central cardiovascular effects of alpha-adrenergic drugs: differences between catecholamines and imidazolines. J Pharmacol Exp Ther 1984; 230: 232-6.
3. Parini A. Du recepteuralpha-2adrenergique aurecepteur imidazolinique -guanidinique: un concept en evolution. Lettre du Pharmacologue 1989; 6(Suppl): 3.
4. Fiorentini C, Guillet C, Guazzi M. Etude multicentrique en double aveugle comparant la rilmenidine 1mg et l’hydrochlorothiazide 25 mg chez 244 patients JAMA 1990; (specialissue): 45-50.
5. Dallocchio M, Gosse P, Fillastre JP, et al. La rilmenidine, un nouvel antihypertenseur dans le traitment de premiere intention de l’hypertentionarterielle essentielle. Etude multicentrique en double aveugle contre atenolol. Arch Mal Coeur Vaiss 1991; 84(special issue): 42.
6. Fillastre JP, Letac B, Galinier F, et al. A multicenter double-blind comparativestudy of rilmenidine and clonidine in 333 hypertensive patients. Am J Cardiol 1988; 61: 81d-5.
7. Scemama M, Fevrier B, Beucler I, et le groupe des medecins Euraxi SA. Lipid profile and anthihypertensive efficacy in dyslipidemic hypertensive patients; comparison of rilmenidine with captopril. J Cardiovasc Pharmacol 1995; 26(Suppl 2): 34-9.
8. Sadowski Z, Szwed H, Kuch-Wocial A, et al. Regression of left ventricular hypertrophy in hypertensive patients after one year treatment with rilmenidine: a double-blind, randomized, controlledstudy versus nifedipine. Lnt Symp 69th Annual Scietntific Session of the AHA New Orleans 1996; Abstract.
9. Luccioni R. Evaluation pharmaco-epidemiologique de la rilmenidine chez 18335 hypertendu. Presse Med 1995; 24: 1857- 64.
10. Ostermann G, Brisgand B, Schmitt J, Fillastre Jp. Efficacy and acceptability ofrilmenidine for mild-to-moderate systemic hypertension. Am J Cardiol 1988; 61: 760-800.
11. Harron DWG, Hasson B, Regan M, et al. Effects of rilmenidine and clonidine on the electroencephalogram, saccadic eye movements, and psychomotor function. J Cardiovasc Pharmacol 1995: 26 (Suppl 2): 48-54.
12. Dollery CT, Wilson IV, Pragnell AA, et al. Rilmenidine in mildto-moderate essential hypertension. A double-blind, randomized parallel-group, multicenter comparison with methyldopa in 157 patients. Curr Ther Res 1990; 47: 194-221.
13. Julius S. Effect of sympathetic overactivity on cardiovascular prognosis in hypertension. Eur Heart J 1998; 19(Suppl. F): F14-8.
14. Небиеридзе Д.В., Оганов Р.Г. Симпатолитики нового поколения: перспективы контроля артериальной гипертонии. Кардиоваск тер профил 2003; 2: 46-52.
Review
For citations:
Nebieridze D.V., Nedogoda S.V. Imidazoline receptor agonists: more than blood pressure reduction? Cardiovascular Therapy and Prevention. 2006;5(2):112-117. (In Russ.)
Views:
1967
Email this article 
